RAFAEL
RUBIO GARCÍA
Profesor titular de universidad
![Foto de RAFAEL](/img/uploaded/6CA654DD031F6FEF08160B3A8AA5CC20.jpg)
![Foto de Hospital Ramón y Cajal](/img/noimage_org.png)
Hospital Ramón y Cajal
Madrid, EspañaPublicacions en col·laboració amb investigadors/es de Hospital Ramón y Cajal (84)
2024
-
Acceptability of Long-Acting Injectable Antiretroviral Treatment for HIV Management: Perspectives of Patients and Physicians in Spain
AIDS Patient Care and STDs, Vol. 38, Núm. 7, pp. 305-314
2023
-
Post-mortem findings in Spanish patients with COVID-19; a special focus on superinfections
Frontiers in Medicine, Vol. 10
2022
-
Discovering HIV related information by means of association rules and machine learning
Scientific Reports, Vol. 12, Núm. 1
-
Management of Comorbidities in Treated HIV Infection: A Long Way to Go: HIV, comorbidities and aging
International Journal of Antimicrobial Agents, Vol. 59, Núm. 1
2021
-
Cryptococcal infection in HIV-infected patients with CD4+ T-cell counts under 100/μL diagnosed in a high-income country: a multicentre cohort study
Clinical Microbiology and Infection, Vol. 27, Núm. 8, pp. 1171.e1-1171.e7
-
Late presentation for HIV remains a major health issue in Spain: Results from a multicenter cohort study, 2004–2018
PLoS ONE, Vol. 16, Núm. 4 April
-
Redefining therapeutic success in HIV patients: An expert view
Journal of Antimicrobial Chemotherapy, Vol. 76, Núm. 10, pp. 2501-2518
2020
-
Effectiveness of the combination elvitegravir/cobicistat/tenofovir/emtricitabine (EVG/COB/TFV/FTC) plus darunavir among treatment-experienced patients in clinical practice: A multicentre cohort study
AIDS Research and Therapy, Vol. 17, Núm. 1
-
Effects of first-line antiretroviral therapy on the CD4/CD8 ratio and CD8 cell counts in CoRIS: a prospective multicentre cohort study
The Lancet HIV, Vol. 7, Núm. 8, pp. e565-e573
-
Virological outcome among HIV infected patients transferred from pediatric care to adult units in Madrid, Spain (1997–2017)
Scientific Reports, Vol. 10, Núm. 1
2019
-
Analysis of the costs and cost-effectiveness of the guidelines recommended by the 2018 GESIDA/Spanish National AIDS Plan for initial antiretroviral therapy in HIV-infected adults
Enfermedades Infecciosas y Microbiologia Clinica, Vol. 37, Núm. 3, pp. 151-159
2018
-
Costs and cost-efficacy analysis of the 2017 GESIDA/Spanish National AIDS Plan recommended guidelines for initial antiretroviral therapy in HIV-infected adults
Enfermedades Infecciosas y Microbiologia Clinica, Vol. 36, Núm. 5, pp. 268-276
-
Impact of co-infection by hepatitis C virus on immunological and virological response to antiretroviral therapy in HIV-positive patients
Medicine (United States), Vol. 97, Núm. 38
-
Low-level viremia is associated with clinical progression in HIV-infected patients receiving antiretroviral treatment
Journal of Acquired Immune Deficiency Syndromes, Vol. 78, Núm. 3, pp. 329-337
-
Neurocognitive safety after 96 weeks on dual therapy with atazanavir/ritonavir plus lamivudine: Results of the neurocognitive substudy of the SALT randomized clinical trial
Journal of Antimicrobial Chemotherapy, Vol. 73, Núm. 9, pp. 2444-2451
-
Role of HIV in the desire of procreation and motherhood in women living with HIV in Spain: A qualitative approach
BMC Women's Health, Vol. 18, Núm. 1
2017
-
Análisis de costes y de coste/eficacia de las pautas recomendadas por GESIDA/Plan Nacional sobre el Sida en 2016 para el tratamiento antirretroviral inicial en adultos infectados por el VIH
Enfermedades Infecciosas y Microbiologia Clinica, Vol. 35, Núm. 2, pp. 88-99
-
Eradication of hepatitis C virus and non-liver-related non–acquired immune deficiency syndrome–related events in human immunodeficiency virus/hepatitis C virus coinfection
Hepatology, Vol. 66, Núm. 2, pp. 344-356
-
Prediction of long-term outcomes of HIV-infected patients developing non-AIDS events using a multistate approach
PLoS ONE, Vol. 12, Núm. 9
-
Simplification to dual therapy (atazanavir/ritonavir1lamivudine) versus standard triple therapy [atazanavir/ritonavir1two nucleos(t)ides] in virologically stable patients on antiretroviral therapy: 96 week results from an open-label, non-inferiority, randomized clinical trial (SALT study)
Journal of Antimicrobial Chemotherapy, Vol. 72, Núm. 1, pp. 246-253